The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. PNR
2. ONON
3. IAUX
4. KKR
5. DAVA
6. MONC:IM
7. MONRY
8. NYXH
9. THO
10. JG

Go back to The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
ALKERMES (NASDAQ: ALKS) Delayed: 44.18 --0 (-0%)
Previous Close $44.18    52 Week High $80.71 
Open $44.18    52 Week Low $27.14 
Day High $44.18    P/E 339.85 
Day Low $44.18    EPS $0.13 
Volume 88